What’s New

Home What’s New

27

Jul2015

Ontario Public Drug Programs Division

Proposal to Amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and ... Read More

20

Jul2015

Exceptional Response to PDCI/H3 Private Payer PLA Survey

PDCI & H3 Survey on Private Payer Product Listing Agreements Now “Closed” for Responses As noted in the June 24th TargetPharma, ... Read More

24

Jun2015

Private Payer PLA Survey

PDCI & H3 Survey on Private Payer Product Listing Agreements Interest, Experience & Expectations Private payers – the community of insurers, ... Read More

23

Jun2015

Australia’s Pharmaceutical Benefits Advisory Committee Recommends Substitution of Biosimilars

Currently in Canada, switching and substitutability between originator biologics and biosimilars has not been established, however that is not the ... Read More